# Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

> **NCT04985357** · — · WITHDRAWN · sponsor: **Travera Inc**

## Conditions studied

- Stage III Breast Cancer
- Stage IV Breast Cancer
- Stage III Lung Cancer
- Stage IV Lung Cancer
- AML
- Multiple Myeloma in Relapse
- Carcinoma
- Carcinoma, Pancreatic
- Carcinoma of Lung
- Carcinoma, Non-Small-Cell Lung
- Carcinoma Breast
- Carcinoma Prostate
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Small Cell Lung
- Carcinoma, Ovarian
- Carcinoma Bladder
- Carcinoma of Esophagus
- Carcinoma Cervix
- Carcinoma, Thymic
- Carcinoma, Ductal
- Carcinoma of the Head and Neck
- Carcinoma of the Lip
- Carcinoma of the Oral Cavity
- Carcinoma of Unknown Primary
- Carcinoma of the Skin
- Carcinoma of the Anus
- Carcinoma of the Larynx
- Carcinoma of the Penis
- Carcinoma of the Oropharynx
- Carcinoma of the Appendix
- Carcinoma of the Paranasal Sinus
- Carcinoma of the Vulva
- Malignant Pleural Effusion
- Malignant Ascites
- Mesothelioma
- Cholangiocarcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04985357
- **Lead sponsor:** Travera Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11
- **Primary completion:** 2028-05
- **Final completion:** 2030-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Abandoned prior to launch.
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04985357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04985357, "Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04985357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*